Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | FOXO1 | Q12778 | 13/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL25425342 | 1.00 | ACHE (0.59) | ACHEFOXO1PDE10ADGAT1KCNH2 | |
| SCHEMBL25425817 | 0.91 | ACHE (0.61) | ACHEFOXO1PDE10ADGAT1KCNH2 | |
| SCHEMBL29524098 | 0.91 | ACHE (0.61) | ACHEFOXO1PDE10ADGAT1KCNH2 | |
| SCHEMBL29524119 | 0.89 | ACHE (0.61) | ACHEFOXO1PDE10ADGAT1KCNH2 | |
| SCHEMBL25426792 | 0.89 | FOXO1 (0.60) | ACHEFOXO1PDE10ADGAT1KCNH2 | |
| SCHEMBL29523569 | 0.89 | FOXO1 (0.60) | ACHEFOXO1PDE10ADGAT1KCNH2 | |
| SCHEMBL25428817 | 0.89 | ACHE (0.61) | ACHEFOXO1PDE10ADGAT1KCNH2 | |
| SCHEMBL25428209 | 0.89 | ACHE (0.61) | ACHEFOXO1PDE10ADGAT1KCNH2 | |
| SCHEMBL25426476 | 0.89 | ACHE (0.61) | ACHEFOXO1PDE10ADGAT1KCNH2 | |
| SCHEMBL29523863 | 0.89 | ACHE (0.61) | ACHEFOXO1PDE10ADGAT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK | 2023-12-28 | — | — | US | disclosed |
| EP-4217355-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Forkhead Biotherapeutics, inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022066938-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FORKHEAD BIOTHERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FOXO1, FOXO3, GCKR | ACHE 4877/4885FOXO1 1/4885PDE10A 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.